Health Care [ 9/12 ] | Biotechnology [ 65/74 ]
NASDAQ | Common Stock
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States.
The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
It is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome.
In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths products.
It has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction.
BioCardia, Inc. is based in Sunnyvale, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 25, 25 | -0.25 Decreased by -177.78% | -0.87 Increased by +71.26% |
| Nov 6, 24 | -0.61 Decreased by -408.33% | -1.19 Increased by +48.74% |
| Aug 13, 24 | -0.88 Decreased by -415.82% | -0.10 Decreased by -776.90% |
| May 14, 24 | -0.09 Increased by +46.94% | -0.20 Increased by +54.90% |
| Mar 27, 24 | -0.09 Increased by +43.75% | -0.11 Increased by +18.18% |
| Nov 8, 23 | -0.12 Increased by +29.41% | -0.12 |
| Aug 9, 23 | -0.17 Decreased by -21.43% | -0.16 Decreased by -6.25% |
| May 10, 23 | -0.17 Increased by +15.00% | -0.16 Decreased by -6.25% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by -100.00% | -2.30 M Decreased by -10.81% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by -100.00% | -1.74 M Increased by +32.52% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 3.00 K Decreased by -93.02% | -1.65 M Increased by +51.93% | Decreased by -54.87 K% Decreased by -589.04% |
| Mar 31, 24 | 55.00 K Decreased by -14.06% | -2.27 M Increased by +35.08% | Decreased by -4.12 K% Increased by +24.46% |
| Dec 31, 23 | 13.00 K Decreased by -87.74% | -2.07 M Increased by +31.80% | Decreased by -15.94 K% Decreased by -456.11% |
| Sep 30, 23 | 357.00 K Increased by +68.40% | -2.57 M Increased by +15.72% | Decreased by -721.01% Increased by +49.95% |
| Jun 30, 23 | 43.00 K Decreased by -95.59% | -3.42 M Decreased by -37.07% | Decreased by -7.96 K% Decreased by -3.00 K% |
| Mar 31, 23 | 64.00 K Increased by +6.67% | -3.49 M Decreased by -5.09% | Decreased by -5.46 K% Increased by +1.48% |